================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 3, 2000
------------------------------
COMMISSION FILE NUMBER 0-17714
------------------------------
Biopool International, Inc.
(Exact name of Registrant as specified in its charter)
DELAWARE 58-1729436
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
6025 NICOLLE STREET
VENTURA, CALIFORNIA 93003
(Address of principal executive offices)
(805) 654-0643
(Registrant's telephone number including area code)
================================================================================
<PAGE>
ITEM 5. OTHER EVENTS
Reference is made to the press release of Registrant, issued on April 3,
2000, which contains information meeting the requirements of this Item 5, and
which is incorporated herein by this reference. A copy of the press release is
attached to this Form 8-K as Exhibit "A."
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: APRIL 5, 2000 BIOPOOL INTERNATIONAL, INC.
-------------------------- ---------------------------
(Registrant)
/S/ MICHAEL D. BICK, PH.D.
--------------------------
Michael D. Bick, Ph.D.
Chief Executive Officer and
Chairman of the Board
2
<PAGE>
EXHIBIT A
CONTACTS: Michael D. Bick, Ph.D.
Chairman and Chief Executive Officer
Carol Hill
Corporate Communications
(805) 654-0643
FOR IMMEDIATE RELEASE
COMPLAINT ALLEGING PATENT INFRINGEMENT FILED
AGAINST BIOPOOL INTERNATIONAL
VENTURA, California (April 3, 2000) -- Biopool International, Inc. (OTC BB:BIPL)
today reported that Agen Biomedical Limited, a wholly-owned subsidiary of
Biotech International Limited (BII.AX), an Australian corporation, filed a
complaint against the Company in U.S. District Court in San Francisco,
California, March 10, 2000. The complaint alleges that Biopool's manufacture and
sale of D-dimer test kits in the U.S. directly infringes Agen's U.S. patent
4,758,524.
Michael D. Bick, Ph.D., chairman and chief executive officer of
Biopool, commented, "We have prepared and filed an answer. We believe the
complaint to be without merit and that it will have no material impact on our
financial position or results of operations."
Founded in 1987, Biopool International develops, manufactures, and
markets a full range of test kits to assess and diagnose disorders of blood
coagulation, thrombotic risk factors, fibrinolysis, platelet function, and the
vascular system and specialty toxicology controls used to monitor and measure
the presence of drugs of abuse. The Company's product line is sold to hospitals,
clinical laboratories, commercial reference laboratories, and research
institutions on a worldwide basis by the Company's own sales representatives, as
well as through an extensive network of distributors. To learn more about
Biopool, visit the Company's website at http://www.biopool.com.
NOTE: This press release contains forward-looking statements including the
expectation that a complaint filed against the Company will have no material
impact on the Company's financial position or results of operations, which are
based upon current expectations that involve a number of risks and uncertainties
including, but not limited to, technological innovations of competitors, changes
in health care regulations, litigation claims, foreign currency fluctuation,
product acceptance or changes in government regulation of the Company's
products, as well as other factors discussed in the Company's last Report on
Form 10-K-SB under "Risk Factors."
# # #
3
